10 recruiting. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Recruiting 10 |
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women Low intensity shockwave therapy, Oral Solifenacin succinate 5 mg - Overactive Bladder (OAB), Urge Incontinence | Phase 4 | Recruiting | Mansoura University | 70 | 2025-11-11 | 2026-03-16 |
| Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study Tadalafil 5 mg, Solifenacin 5mg - Overactive Bladder (OAB), Overactive Bladder Syndrome | Phase 4 | Recruiting | Mansoura University | 480 | 2025-09-01 | 2026-02-18 |
| Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection Methenamine Hippurate, Typically prescribed oral antibiotic prophylaxis - Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis) | Phase 4 | Recruiting | Women and Infants Hospital of Rhode Island | 164 | 2025-08-01 | 2026-08-19 |
| Bladder Botox UTI Antibiotic Prophylaxis Nitrofurantoin 100 MG - Overactive Bladder, Bladder Pain Syndrome | Phase 4 | Recruiting | Walter Reed National Military Medical Center | 100 | 2024-04-04 | 2025-02-19 |
| TReating Incontinence for Underlying Mental and Physical Health Tolterodine Tartrate ER, Mirabegron, Placebo - Urinary Incontinence, Urge, Urinary Incontinence | Phase 4 | Recruiting | University of California, San Francisco | 270 | 2022-10-04 | 2026-03-06 |
| Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity Solifenacin with vaginal estrogen cream, Combination pharmacotherapy - Urinary Bladder, Overactive, Effect of Drug | Phase 4 | Recruiting | Mackay Memorial Hospital | 200 | 2022-06-16 | 2025-05-09 |
| Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder Combined pharmacotherapy with Solifenacin and Mirabegron, Solifenacin with vaginal estrogen cream, Mirabegron with vaginal estrogen cream - Effect of Drug, Urinary Bladder, Overactive | Phase 4 | Recruiting | Mackay Memorial Hospital | 300 | 2022-06-16 | 2025-05-09 |
| Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity Intradetrusor Botox® (onabotulinumtoxinA) injection, Combine Mirabegron and Solifenacin. - Urinary Bladder, Overactive, Urodynamics | Phase 4 | Recruiting | Mackay Memorial Hospital | 300 | 2021-10-01 | 2025-05-09 |
| Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A OnabotulinumtoxinA 100 UNT - Urinary Bladder, Overactive, Incontinence, Urge | Phase 4 | Recruiting | University of South Florida | 60 | 2019-10-09 | 2020-11-05 |
| Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder onaBoNT-A - Overactive Bladder | Phase 4 | Recruiting | Walter Reed National Military Medical Center | 184 | 2019-07-01 | 2020-04-28 |
Urinary Incontinence, Urge (4) · Urinary Incontinence (2) · Urinary Tract Infections (2) · Cystitis, Interstitial (1) · Disease (1) · Nocturia (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Lower Urinary Tract Symptoms (10) · Male Urogenital Diseases (10) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (10) · Urinary Bladder Diseases (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Urological Manifestations (10) · Urination Disorders (4) · Infections (2) · Urinary Incontinence (2) · Cystitis (1) · Pathologic Processes (1)
Solifenacin Succinate (5) · Botulinum Toxins, Type A (3) · mirabegron (3) · Estrogens, Conjugated (USP) (2) · Anti-Bacterial Agents (1) · Drug Therapy, Combination (1) · Injections (1) · Nitrofurantoin (1) · Tadalafil (1) · Tolterodine Tartrate (1) · methenamine hippurate (1) · onabotulinum toxin A (1)
Mackay Memorial Hospital (3) · Mansoura University (2) · Walter Reed National Military Medical Center (2) · University of California, San Francisco (1) · University of South Florida (1) · Women and Infants Hospital of Rhode Island (1)
United States (5) · Taiwan (3) · Egypt (2)
Hui-Hsuan Lau, MD (3) · Ahmed A Shokeir, professor of urology (1) · Alison Huang, MD, MAS, MPhil (1) · Angela DiCarlo-Meacham, MD (1) · Eric S Chang, MD (1) · Jordan Gisseman, MD (1) · Sherif Mourad, Professor of Urology (1) · Vivian Sung, MD, MPH (1)
PMID 35543540, PMID 37085880, PMID 40590342
R01AG075471 (1)